

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representation of  
The original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 9/127, 31/70</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/15154</b> <b>(43) International Publication Date:</b> 8 June 1995 (08.06.95)
<b>(21) International Application Number:</b> PCT/GB94/02506 <b>(22) International Filing Date:</b> 14 November 1994 (14.11.94) <b>(30) Priority Data:</b> 9324852.4      3 December 1993 (03.12.93)      GB <b>(71) Applicant (for all designated States except US):</b> KAPPA PHARMACEUTICALS LIMITED [GB/GB]; Alexander House, Gatchampton Road, Goring on Thames, Reading, Berkshire RG8 0EN (GB). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> OWEN, Roderick, Richard [GB/GB]; Kappa Pharmaceuticals Limited, Alexander House, Gatchampton Road, Goring on Thames, Reading, Berkshire RG8 0EN (GB). <b>(74) Agents:</b> McNEIGHT, David, Leslie et al.; McNeight & Lawrence, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).	<b>(81) Designated States:</b> JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> A MEDICAMENT FOR THE TREATMENT OF METASTASES  <b>(57) Abstract</b>  There is disclosed a medicament for the treatment of hepatic metastases comprising 5-fluoro-2-deoxyuridine entrapped in liposomes, in a pharmaceutically acceptable carrier.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

## A MEDICAMENT FOR THE TREATMENT OF METASTASES

This invention concerns a medicament for the treatment of metastases, especially, though by no means exclusively, for the treatment of hepatic metastases of colorectal adenocarcinoma, and method of manufacturing same.

Colorectal adenocarcinoma is a major cause of death in Western societies with over 55,000 deaths per year in the United States and 20,000 deaths per year in Great Britain.

A majority of those deaths are caused by the secondary tumours, or metastases, produced from the primary tumour. In the case of colorectal adenocarcinoma, these metastases tend to form in the liver.

At present, chemotherapy is used to treat the majority of patients with colorectal adenocarcinoma, with 5 Fluoruracil (5-FU) being the drug of choice. However, a major drawback to this therapy is its high toxicity. The major toxicity of 5-FU is myelosuppression. In addition, alopecia is frequently encountered and mucocitis, nausea and vomiting are common.

More recently, a combined therapy of 5-FU and leucovorin has proved more beneficial to patients in efficacy against the metastases of colorectal adenocarcinoma.

- 2 -

However, a major side effect of the combination therapy is severe, life threatening and occasionally fatal diarrhoea since this drug therapy inhibits DNA synthesis of both normal colonic mucosal cells as well as colorectal tumour cells.

Thus an alternative drug delivery system which would by-pass the normal gut mucosal cells but deliver cytotoxic concentrations to hepatic metastases is required.

Liposomes are suitable candidates as liposome-entrapped drugs are taken up by macrophages and monocytes and are delivered through fenestrated endothelium to such organs as liver, spleen and bone marrow following their intravenous injection, thereby reducing systemic toxicity associated with chemotherapeutic drugs.

However, 5-FU does not lend itself well to liposomal entrapment and, additionally, even when delivered to macrophages in liposomes, 5-FU rapidly leaves these cells by osmosis.

The present invention provides a medicament for the treatment of hepatic metastases which overcomes, at least to some extent, the problem aforesaid.

According to the present invention there is provided a medicament for the treatment of hepatic metastases comprising 5-fluoro-2-deoxyuridine entrapped in liposomes, in a pharmaceutically acceptable carrier.

5-fluoro-2-deoxyuridine (Floxuridine, FudR) is an analogue of 5-FU which is more suitable than 5-FU for liposomal entrapment and will remain within the cells to

- 3 -

which it is delivered in liposomes. FUdR also has a shorter plasma half life, probably less than ten minutes, a higher first-pass liver uptake and is less toxic than 5-FU.

FUdR is also a more effective cytotoxic drug, being four times more effective at inhibiting DNA synthesis via inhibition of thymidyl synthetase than 5-FU (The Cancer Chemotherapy Handbook : Eds Fischer, D S and Knopf, M T, 3rd Edition; Medical Publishers Inc, Chicago and London, 1989).

The medicament may also comprise free leucovorin or free leucovorin may be given at the same time as the FUdR-liposomes. This combined therapy, administered systemically, will be cytotoxic to liver tumours whilst protecting colon and other tissues which will not take up the entrapped drug.

Additionally, this combined therapy is anticipated to be a much more effective therapy than the currently used 'gold standard' therapy of free 5-FU and leucovorin, since free FUdR is known to be even more strongly synergistic with leucovorin than is 5-FU (The Cancer Chemotherapy Handbook, 1989).

The medicament may be administered by any route capable of delivering an effective dose of FUdR-liposomes to the liver.

Preferably, the route of administration of FUdR-liposomes is via intravenous injection.

The liposomes may comprise cholesterol, cholesterol sulphate and

- 4 -

phosphatidyl choline, and preferably 50% cholesterol, 5% cholesterol sulphate and 45% phosphatidyl choline.

The pharmaceutically acceptable carrier may comprise 0.9% saline.

The invention also comprises a method of manufacture of FUdR-liposomes for the treatment of hepatic metastases comprising the following steps:

1. Mixing together cholesterol, cholesterol sulphate and phosphatidyl choline
2. Depyrogenation
3. Drying
4. Lyophilisation
5. Addition of aqueous FUdR
6. Filtration
7. Sterilisation
8. Suspension of the resulting FUdR-liposomes in a pharmaceutically acceptable carrier.

An example of this method of manufacture comprises mixing together 90mg of hydrogenated phosphatidyl choline, 10mg of cholesterol sulphate and 40mg of cholesterol. This mixture is then depyrogenated by filtration through glass fibre and cellulose filters and then dried by rotary evaporation before being lyophilised under high vacuum. An aqueous solution of FUdR (400mg FUdR in 5ml water) is then admixed with the dried liposomes and the final preparation passed through a series of 0.2 micron filters and finally passed through a sterilisation filtration.

- 5 -

This method generally results in an entrapment of FUdR of around 70%. Such FUdR-liposomes have been shown to be stable up to ten weeks with a small leakage of FUdR occurring after that time.

It is envisaged that patients will be given approximately 30mg/kg/day of the above mentioned FUdR-liposomes daily for five days in 0.9% saline via intravenous injection. Leucovorin will also be administered daily at 50mg/m<sup>2</sup> over two hours with the liposomal FUdR given as a bolus dose at the midpoint.

It will be appreciated that it is not intended to limit the invention to the above example only, many variations, such as might readily occur to one skilled in the art being possible, without departing from the scope thereof.



CLAIMS

1. A medicament for the treatment of hepatic metastases comprising 5-fluoro-2-deoxyuridine entrapped in liposomes, in a pharmaceutically acceptable carrier.
2. A medicament according to claim 1 further comprising free leucovorin.
3. A medicament according to either claim 1 or claim 2 wherein the liposomes comprise cholesterol, cholesterol sulphate and phosphatidyl choline.
4. A medicament according to any preceding claim wherein the pharmaceutically acceptable carrier comprises saline or dextrose solution.
5. A method of manufacture of FUdR-liposomes for the treatment of hepatic metastases comprising the following steps;
  1. Mixing together cholesterol, cholesterol sulphate and phosphatidyl choline,
  2. Depyrogenation
  3. Drying
  4. Lyophilisation
  5. Addition of aqueous FUdR
  6. Filtration
  7. Sterilisation
  8. Suspension of the resulting FUdR-liposomes in a pharmaceutically acceptable carrier

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 94/02506

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K9/127 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 9315 Derwent Publications Ltd., London, GB; AN 93-121261 & JP,A,05 058 879 (TAIHO PHARM CO LTD) , 9 March 1993 see abstract	1,4,5
Y	---	2,3
X	JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66,no. 07, July 1977 WASHINGTON, DC (US), pages 984-986, S.P. SIMMONS ET AL. 'liposomal entrapment of floxuridine' see the whole document --- -/-	1,4,5

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

5 April 1995

Date of mailing of the international search report

21. 04. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Benz, K

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 94/02506

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 108, no. 11, 14 March 1988 Columbus, Ohio, US; abstract no. 87669v, G.L. SCHERPHOF ET AL. 'liposomes in chemo- and immunotherapy of cancer' page 27; column 1; see abstract & LIPIDS, vol. 22, no. 11, 1987 pages 891-896, ---	1,4,5
Y	CHEMICAL ABSTRACTS, vol. 117, no. 5, 3 August 1992 Columbus, Ohio, US; abstract no. 39925q, M. IIGO ET AL. 'in vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin' page 34; column 1; see abstract & JPN. J. CANCER RES., vol. 83, no. 4, 1992 pages 392-396, ---	2
Y	EP,A,0 278 465 (KABUSHIKI KAISHA VITAMIN KENKYUSYO) 17 August 1988 see the whole document -----	3

### Information on patent family members

PCT/GB 94/02506

Form PCT/ISA/210 (patent family annex) (July 1992)